Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder preservation: a viable alternative to radical surgery?

NCT ID NCT07744958

Knowledge-focused Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This registry study follows bladder cancer patients who, after receiving systemic therapy, choose not to undergo bladder removal (cystectomy) or radiotherapy. The goal is to collect data on their outcomes, such as metastasis-free survival, to better understand which patients might safely preserve their bladder. By analyzing this real-world data, researchers hope to identify factors that make bladder preservation a medically sound option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could help identify which bladder cancer patients can safely avoid bladder removal, preserving quality of life without compromising cancer control.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove whether bladder preservation is as effective as surgery. Results may be limited by patient selection and lack of a comparison group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with muscle-invasive urothelial carcinoma of the bladder who decline to undergo radical cystectomy or radiotherapy after systemic therapy (perioperative attempt)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged \>= 18 years, capable of providing informed consent * Histologically confirmed muscle-invasive urothelial carcinoma of the urinary bladder * Received perioperative systemic therapy in accordance with current guidelines and subsequently decline cystectomy or radiotherapy Exclusion Criteria: * Age \< 18 years * Lack of capacity to provide informed consent * No histological confirmed muscle-invasive urothelial carcinoma * No prior preoperative systemic therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle invasive bladder cancer (MIBC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle invasive bladder cancer (MIBC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.